Literature DB >> 30963001

Risk of recurrence in stage I adenocarcinoma of the lung: a multi-institutional study on synergism between type of surgery and type of nodal staging.

Francesco Guerrera1,2, Filippo Lococo3, Andrea Evangelista4, Ottavio Rena5, Luca Ampollini6, Jacopo Vannucci7, Luca Errico8, Paolo Olivo Lausi1,2, Luigi Ventura6, Valentina Marchese1, Massimiliano Paci3, Pier Luigi Filosso1,2, Alberto Oliaro1,2, Caterina Casadio4, Francesco Puma7, Enrico Ruffini1,2, Francesco Ardissone8.   

Abstract

BACKGROUND: In last years, an increasing interest emerges on the role of sub-lobar resection and lobe-specific lymph nodal dissection in the treatment of early-stage lung cancer. The aim of our study was to define the impact on cumulative incidence of recurrence (CIR) of type of surgical resection and type of nodal staging in this subset of patients. Furthermore, we evaluated the possible synergism between the different kinds of procedure.
METHODS: An analysis of 969 consecutive stage I pulmonary adenocarcinoma patients, operated in six Thoracic Surgery Institutions between 2001 and 2013, was conducted. Type of surgical resection included lobectomy and sub-lobar resection; while pneumonectomy and bilobectomy were excluded from the analysis. Nodal staging procedures were classified in nodal sampling (NS), lobe-specific lymph node dissection (LS-ND) and systematic lymph node dissection (SND). Multivariable-adjusted comparisons for CIR was performed using Fine and Grey model, taking into account of death by any cause as competing event. In order to evaluate synergism between the different procedures, the test of interaction between type of surgical resection and type of nodal staging was carried out and results presented in a stratified way.
RESULTS: Eight-hundred forty-six (87%) patients were submitted to lobectomy, while 123 (13%) to sub-lobar resection. Four-hundred fifty-five (47%) patients received SND, 98 (10%) LS-ND and 416 (43%) NS. Two-hundred forty-seven (26%) patients developed a local/distant recurrence with a 5-year CIR of 24.2%. Multivariable-adjusted comparisons showed an independent negative effect of sub-lobar resection (HR =1.52; 95% CI: 1.07-2.17), LS-ND (HR =1.74; 95% CI: 1.16-2.6) and NS (HR =1.49; 95% CI: 1.12-1.98) on CIR. Test of interaction showed a homogeneity of results among subgroups.
CONCLUSIONS: Patients affected by stage I pulmonary adenocarcinoma and submitted to lobectomy presented a significant lower recurrence rate than those submitted to sub-lobar resection. Moreover, SND presented an independent positive effect on recurrence development than other lymph node assessment strategy. Finally, lobectomy in combination with systematic lymph nodal resection showed the best results in term of CIR.

Entities:  

Keywords:  Non-small cell lung cancer (NSCLC); lobectomy; lymphadenectomy; staging

Year:  2019        PMID: 30963001      PMCID: PMC6409264          DOI: 10.21037/jtd.2019.01.31

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  36 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer.

Authors:  Didier Lardinois; Paul De Leyn; Paul Van Schil; Ramon Rami Porta; David Waller; Bernward Passlick; Marcin Zielinski; Toni Lerut; Walter Weder
Journal:  Eur J Cardiothorac Surg       Date:  2006-09-12       Impact factor: 4.191

3.  Factors associated with outcome of segmentectomy for non-small cell lung cancer: long-term follow-up study at a single institution in Japan.

Authors:  Meinoshin Okumura; Masashi Goto; Kan Ideguchi; Mitsunobu Tamura; Hidefumi Sasaki; Hisaichi Tanaka; Akihide Matsumura; Keiji Iuchi
Journal:  Lung Cancer       Date:  2007-07-30       Impact factor: 5.705

4.  Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database.

Authors:  Carlos M Mery; Anastasia N Pappas; Raphael Bueno; Yolonda L Colson; Philip Linden; David J Sugarbaker; Michael T Jaklitsch
Journal:  Chest       Date:  2005-07       Impact factor: 9.410

5.  Is segmentectomy with lymph node assessment an alternative to lobectomy for non-small cell lung cancer of 2 cm or smaller?

Authors:  M Okada; K Yoshikawa; T Hatta; N Tsubota
Journal:  Ann Thorac Surg       Date:  2001-03       Impact factor: 4.330

6.  Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study.

Authors:  Morihito Okada; Teruaki Koike; Masahiko Higashiyama; Yasushi Yamato; Ken Kodama; Noriaki Tsubota
Journal:  J Thorac Cardiovasc Surg       Date:  2006-10       Impact factor: 5.209

7.  Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis.

Authors:  Amgad El-Sherif; William E Gooding; Ricardo Santos; Brian Pettiford; Peter F Ferson; Hiran C Fernando; Susan J Urda; James D Luketich; Rodney J Landreneau
Journal:  Ann Thorac Surg       Date:  2006-08       Impact factor: 4.330

8.  Sublobar resection for lung cancer.

Authors:  R Rami-Porta; M Tsuboi
Journal:  Eur Respir J       Date:  2009-02       Impact factor: 16.671

9.  Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial.

Authors:  Mark S Allen; Gail E Darling; Taine T V Pechet; John D Mitchell; James E Herndon; Rodney J Landreneau; Richard I Inculet; David R Jones; Bryan F Meyers; David H Harpole; Joe B Putnam; Valerie W Rusch
Journal:  Ann Thorac Surg       Date:  2006-03       Impact factor: 4.330

10.  Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer.

Authors:  Teruaki Koike; Yasushi Yamato; Katsuo Yoshiya; Takehiko Shimoyama; Ryuta Suzuki
Journal:  J Thorac Cardiovasc Surg       Date:  2003-04       Impact factor: 5.209

View more
  3 in total

Review 1.  [The technique of thoracic lymph node dissection].

Authors:  S Oguzhan; M Mese; M Schirren; M Baladov; J Schirren
Journal:  Chirurg       Date:  2019-12       Impact factor: 0.955

2.  A glimpse of the future?-bronchoscopic ablation of peripheral early stage lung cancer.

Authors:  Daniel P Steinfort; Kanishka Rangamuwa
Journal:  Transl Lung Cancer Res       Date:  2021-10

3.  Lobe-Specific Node Dissection Can Be a Suitable Alternative to Systematic Lymph Node Dissection in Highly Selective Early-Stage Non-Small-Cell Lung Cancer Patients: A Meta-Analysis.

Authors:  Zihuai Wang; Zhuoran Qi; Diou Cheng; Xiaohu Hao; Qiang Pu; Lunxu Liu
Journal:  Ann Thorac Cardiovasc Surg       Date:  2020-12-07       Impact factor: 1.520

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.